stichd to Become Official Merchandise Partner of Aston Martin Aramco Cognizant Formula One® Team
7.6.2023 11:00:00 EEST | Business Wire | Press release
Global licensing partner stichd has signed a long-term agreement with the Aston Martin Aramco Cognizant Formula One® Team (AMF1 Team), which gives it the exclusive rights to design, produce and distribute the group’s fanwear products starting in 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005415/en/
Global licensing partner stichd has signed a long-term agreement with the Aston Martin Aramco Cognizant Formula One® Team (AMF1 Team), which gives it the exclusive rights to design, produce and distribute the group’s fanwear products starting in 2024. (Graphic: Business Wire)
stichd, part of the PUMA Group, will gain global distribution rights to sell AMF1 Team’s branded apparel and accessories for men, women and kids across several online and offline channels. It will also become the official e-commerce partner of the team.
“We are beyond excited to join forces with AMF1 Team,” said Nina Nix, CEO of stichd. “As F1® and Aston Martin continue to grow its momentum, we are ready to translate this passion into fashion-forward apparel and accessories. And we really look forward to doing this with the AMF1 team.”
stichd, a company for licensed fanwear and lifestyle apparel as well as legwear, bodywear and swimwear, will make AMF1 Team’s official merchandise available on amf1.com, the Fuel for Fans online store and other online and offline stores.
“We really feel the passion and intensity of our fans,” said Jefferson Slack, AMF1 Team Managing Director, Commercial & Marketing. “This year, we’ve witnessed huge growth in our audience – particularly as the team’s on-track performances have improved. A lot of what we do as a team is directed towards surprising and delighting our fanbase. Partnering with stichd to make official fanwear available to everyone is a fantastic opportunity, and we look forward to working closely with them on next year’s first collection.”
Starting in 2024, stichd will also have the exclusive rights to operate the fan retail stores during every Formula One® race weekend. At these stores, stichd will sell Formula One® products as well as team replica, fanwear, and special-edition collections – including AMF1 fanwear, teamwear, drivers’ specials and replica versions of the team kit.
stichd’s parent company PUMA is the leading provider of race gear for drivers, teamwear and merchandise products in Formula One® and other motorsport series.
The first products of stichd’s new partnership with AMF1 will be available at the start of the 2024 FIA Formula One World Championship season.
About stichd
stichd is a trusted brand partner with its head office located in ‘s-Hertogenbosch, Netherlands. Employing over 700 people, the company’s current brand partners include: PUMA, Tommy Hilfiger, Levi’s, Head, Calvin Klein, Mercedes-AMG Petronas Formula One Team, Scuderia Ferrari, Porsche Motorsport, Ayrton Senna, Formula 1, Formula E, BMW Lifestyle and Motorsport and Manchester City Football Club. From branded socks and underwear to fashionable swimwear, fanwear and lifestyle apparel and accessories, stichd is proud to make products that are universal and personal to everyone. At stichd, products are seen as humble heroes -pieces that are intimate and prized by many. By partnering with an array of global A-list brands, stichd makes exceptional products for a global audience; striking a balance between understanding the multiple brands and markets, while making products people love. With the mission to Consciously Craft Convenience, stichd is continuously innovating, remaining a leader in fashion essentials, fanwear and lifestyle. For more information, please visit www.stichd.com
About Aston Martin Aramco Cognizant Formula One® Team
The legendary Aston Martin marque first raced in Formula One in 1959 and returned to the sport in 2021 under the leadership of Canadian entrepreneur Lawrence Stroll. With a team of passionate people at its heart, and a talented squad of drivers – including double World Champion Fernando Alonso and Canada’s Lance Stroll – this is a team with both a rich heritage and a fresh perspective. Alongside collaborative and strategic partners, the Silverstone-based team is bringing new energy to the sport with a determination to shake up the order and compete at the sharp end.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005415/en/
Contact information
Media Contact stichd: Bart Speet | bart.speet@stichd.com
Media Contact AMF1: Steve Cooper | stephen.cooper@astonmartinf1.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom